“We're accelerating that into a Phase III program for head and neck cancer”

In context

“a late-line population with a 31% overall response rate and a median overall survival, albeit a single-line experience of 16.3 months. So that gives us confidence in SV. It's a vedotin payload. So what we've seen with the other studies with vedotin payloads, including with TIVDAK and Padcev was this potentially synergistic activity when we combine it with an anti-PD-1. So SV plus pembrolizumab has now been combined. As you know, overall, we've seen a response rate of approximately 60%. But in those -- in the population specifically, that's TPS high or PD-L1 high expression, all patients so far in the Phase I trial have responded. And that obviously is very favorable to what you would expect from pembrolizumab alone. The next molecule, PDL1V, that's, again, another first-in-class molecule. We're accelerating that into a Phase III program for head and neck cancer, where we've seen a response rate just shy of 60% in the combination with pembrolizumab. And then there's a whole new group of ADCs coming with a TOPO1 payload, including a follow-up to ADCETRIS that currently 2 or 3 of these molecules showing highly encouraging data in Phase I, and we'll update you in the future about those. Albert Bourla: Thank you. So as I said, we are confident that not only we will recuperate the investment with a good return in the season, but I think it's transforming our oncology portfolio and business. Next question, please. Operator: We'll go next to Carter Gould with Cantor. Carter Lewis Gould: I'm going to go back to the policy side. I guess, Albert, should investors have any expectation around a comprehensive deal that addresses the President's objectives acr”